TDOC Teladoc Health, Inc.
Services-Offices & Clinics of Doctors of Medicine · NYSE · SEC CIK 1477449 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-2.4%
TTM net income YoY30.8%
TTM EPS YoY31.7%
Revenue 3-yr CAGR-1.5%
Net income 3-yr CAGR—
Margins
Gross margin68.6%
Operating margin-6.6%
Net margin-6.3%
FCF margin10.6%
EBITDA margin—
Returns
ROE-11.5%
ROA-5.5%
ROIC (approx.)-23.2%
Asset turnover0.87x
Leverage & solvency
Liabilities / assets53.3%
Debt / equity0.00x
Current ratio0.87x
Interest coverage-8.00x
Cash quality & payout
Operating cash flow / net income-1.73x
Accruals ratio-15.0%
Payout ratio—
Capex / revenue0.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $2.53B | $2.57B |
| Cost of revenue | $771.59M | $751.27M |
| Gross profit | $1.76B | $1.82B |
| R&D expense | $277.92M | $307.27M |
| SG&A expense | $431.89M | $435.49M |
| Operating income | -$262.95M | -$1.02B |
| Interest expense | $19.71M | $23.80M |
| Pretax income | -$235.53M | -$993.65M |
| Income tax | -$35.21M | $7.59M |
| Net income | -$200.32M | -$1.00B |
| EPS (basic) | -1.14 | -5.87 |
| EPS (diluted) | -1.14 | -5.87 |
| Weighted avg. shares (diluted) | 176.22M | 170.56M |
| Balance sheet | ||
| Cash & equivalents | $781.08M | $1.30B |
| Receivables | $192.83M | $214.15M |
| Inventory | $38.20M | $38.14M |
| Current assets | $1.12B | $1.66B |
| PP&E, net | $26.97M | $29.49M |
| Goodwill | $283.19M | $283.19M |
| Intangibles | $1.30B | $1.43B |
| Total assets | $2.86B | $3.52B |
| Current liabilities | $404.74M | $941.53M |
| Total liabilities | $1.47B | $2.03B |
| Shareholders' equity | $1.39B | $1.49B |
| Shares outstanding | 178.32M | 173.41M |
| Cash flow statement | ||
| Operating cash flow | $294.36M | $293.68M |
| Capital expenditure | $8.89M | $10.79M |
| Free cash flow | $285.46M | $282.89M |
| Investing cash flow | -$266.00M | -$124.05M |
| Financing cash flow | -$551.65M | $8.31M |
| Stock-based compensation | $80.41M | $145.95M |
Free plan shows the latest 2 periods; Pro shows all 13 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.